TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins and market share gains. Read why TMDX stock is a buy.
TransMedics (TMDX) stock surges as the company reports better-than-expected financials for Q3 and raises its 2026 outlook. Read more here.
TransMedics Group reported third quarter 2026 revenue of US$203.01 million and net income of US$17.07 million. The company raised full year revenue guidance, citing record case volumes and broader use of its organ care and logistics platform. The business increased revenue while industry donor volumes declined, suggesting TransMedics Group is capturing a larger share of organ procedures through its Liver and Heart offerings and its expanding logistics network. We will examine how TransMedics...
TransMedics (TMDX) stock is up 20% in early trading after reporting exceptional Q3 earnings on November 6.
Motley Fool Press Release.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York on Tuesday, November 10, 2026, at 10:40 a.m. EST, the Jefferies Global Healthcare Conference in
Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraftBROOMFIELD, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Gogo (NASDAQ: GOGO) today announced that TransMedics, the global leader in organ transplantation technology, services and logistics, has selected Gogo Galileo to equip its growing fleet of 22 Embraer Phenom 300E aircraft operating across the United States. The aircraft play a critical
About two years ago I called TransMedics Group (TMDX) an interesting stock, but not for those with the faint-hearted.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
TransMedics Group has seen its share price slide in recent months after a strong multi‑year run, which raises an obvious question for you as an investor. Is the current US$78.64 price still aligned with what the company is earning today, or has sentiment moved ahead of the underlying profit story? Over the past 5 years the stock has gained about 157.4%, which puts real weight on whether the earnings profile can support where the valuation now sits. The business relies on turning highly...
Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.
TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform. Read more on TMDX stock here.
Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.
These companies' sell-offs may have gone too far.
Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.